Evidence map›Paper›PMID 30763623›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2019

Mechanistic insights into the pH-dependent membrane peptide ATRAM.

Vanessa P Nguyen, Loganathan Palanikumar, Stephen J Kennel, Daiane S Alves, Yujie Ye, Jonathan S Wall, Mazin Magzoub, Francisco N Barrera

Open access · greenAbstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Vanessa P NguyenDepartment of Biochemistry & Cellular and Molecular Biology, University of Tennessee, Knoxville, TN, United States.
Loganathan PalanikumarBiology Program, Division of Science, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates.
Stephen J KennelDepartments of Medicine & Radiology, University of Tennessee Medical Center, Knoxville, TN, United States.
Daiane S AlvesDepartment of Biochemistry & Cellular and Molecular Biology, University of Tennessee, Knoxville, TN, United States.
Yujie YeDepartment of Biochemistry & Cellular and Molecular Biology, University of Tennessee, Knoxville, TN, United States.
Jonathan S WallDepartments of Medicine & Radiology, University of Tennessee Medical Center, Knoxville, TN, United States.
Mazin MagzoubBiology Program, Division of Science, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates.
Francisco N BarreraDepartment of Biochemistry & Cellular and Molecular Biology, University of Tennessee, Knoxville, TN, United States. Electronic address: fbarrera@utk.edu.
University of Tennessee at Knoxville · USNew York University Abu Dhabi · AEUniversity of Tennessee Medical Center · US

Funding

Preclinical Diagnostic Imaging of AmyloidR01DK079984 · NIDDK · UNIVERSITY OF TENNESSEE KNOXVILLE · PI WALL, JONATHAN S · 2009 to 2016
$3.4M
Transmembrane Peptides for Targeting Acidosis - Equipment SupplementR01GM120642 · NIGMS · UNIVERSITY OF TENNESSEE KNOXVILLE · PI BARRERA, FRANCISCO NICOLAS · 2016 to 2020
$1.7M
NIDDK NIH HHS R01 DK079984NIGMS NIH HHS R01 GM120642
6 · The paper itself

Abstract

pH-responsive peptides are promising therapeutic molecules that can specifically target the plasma membrane in the acidified extracellular medium that bathes cells in tumors. We designed the acidity-triggered rational membrane (ATRAM) peptide to have a pH-responsive membrane interaction. At physiological pH, ATRAM binds to the membrane surface in a largely unstructured conformation, while in acidic conditions it inserts into lipid bilayers forming a transmembrane helix. However, the molecular mechanism ATRAM uses to target and insert into tumor cells remains poorly understood. Here, we determined that ATRAM inserts into cancer cells with a preferential membrane orientation, where the C-terminus of the peptide traverses the plasma membrane and explores the cytoplasm. Using biophysical techniques, we determined that the membrane interaction of ATRAM is contingent on the concentration of the peptide. Kinetic studies showed that membrane insertion occurs in at least three steps, where only the first step was affected by the membrane density of ATRAM. These observations, combined with membrane binding and leakage data, indicate that the interaction of ATRAM with lipid membranes is dependent on its oligomerization state. SPECT/CT imaging in mice revealed that ATRAM accumulates in the blood pool, where it has a prolonged circulation time (> 4 h). Since fast peptide clearance and degradation in circulation are major problems for clinical development, we studied the mechanism ATRAM uses to remain in the blood stream. Using binding and transfer assays, we determined that ATRAM binds reversibly to human serum albumin. We propose that ATRAM uses albumin as a carrier in the blood stream to evade clearance and proteolysis before interacting with the plasma membrane of cancer cells. We also show that ATRAM is able to be deliver liposomes to cells in a pH dependent way. Our data highlight the potential of ATRAM as a specific therapeutic agent for diseases that lead to acidic tissues, including cancer.

Indexed as

AnimalsBreast NeoplasmsCell MembraneFemaleHumansHydrogen-Ion ConcentrationLipid BilayersLiposomesMCF-7 CellsMembrane LipidsMembrane ProteinsMiceMice, Inbred BALB CPeptidesSerum Albumin, HumanLipid BilayersLiposomesMembrane LipidsMembrane ProteinsPeptidesSerum Albumin, Human

Identifiers

PMID30763623
PMCPMC6408977
OpenAlexW2913392941

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.